Health Venture's Chief Is In Talks to Step Aside -- WSJ
May 09 2020 - 3:02AM
Dow Jones News
By Anna Wilde Mathews and David Benoit
This article is being republished as part of our daily
reproduction of WSJ.com articles that also appeared in the U.S.
print edition of The Wall Street Journal (May 9, 2020).
Atul Gawande is in advanced discussions to step down as chief
executive and take on a less operational role as chairman of Haven,
the health-care venture backed by Amazon.com Inc., Berkshire
Hathaway Inc. and JPMorgan Chase & Co., according to people
with knowledge of the matter.
Dr. Gawande, a prominent surgeon and professor at Harvard
University, wants to move away from day-to-day management of Haven
and focus more on policy and advocacy work, particularly related to
the current coronavirus pandemic, the people said.
Haven has launched a search for a new CEO, but has yet to settle
on a candidate, the people said. There hasn't been a final decision
on the leadership structure, the people cautioned.
His transition suggests the health-care venture's slow start
since its splashy unveiling in January 2018. The venture has shown
few public signs of impact, after its announcement by the three
parent companies rattled health-care investors and pushed down the
shares of major insurers.
The founding companies framed the venture as an altruistic
effort to overhaul health care, reining in costs and improving
outcomes, and said they would start with their own employees.
Dr. Gawande took the helm of Haven in July 2018.
Despite the initial hype, the venture's efforts so far have been
of limited scope. It has launched pilot projects testing
health-benefits approaches. This included a program for around
30,000 JPMorgan employees in Ohio and Arizona, who were given a
menu of flat costs for health-care services, according to people
with knowledge of the matter.
Haven has been spending much of its early time building data
systems on employee health-care tendencies across the three
companies, these people said.
An author known for his work on health-care quality, Dr. Gawande
was a high-profile choice to lead the venture. His hiring was seen
as a signal that the partners' ambitions were set higher than
conventional tweaks to health coverage.
Yet Dr. Gawande, who kept his Harvard University professorship
and continued to write for the New Yorker magazine, had little
background in the operational nitty gritty of health insurance or
running a major company. That may have led to stumbles in the
venture's efforts to craft transformative programs, different
people familiar with the matter have said.
Dr. Gawande chose a gradual approach of testing ideas at smaller
scale first, a person with knowledge of the discussions said.
Last year, the company lost its chief operating officer and Dr.
Gawande had been seeking someone to take more operational
responsibility, the people with knowledge of the talks said.
The venture was initially seen as a threat by traditional health
companies. Some even complained to JPMorgan about the partnership,
and Chief Executive James Dimon got involved personally to speak
with some health-care executives and allay fears the bank would be
competing with them.
UnitedHealth Group Inc., sued to block a former employee of its
Optum health-services unit who went to work for the venture, but a
judge declined to issue a restraining order. UnitedHealth is also
the parent of the largest U.S. health insurer.
Write to Anna Wilde Mathews at anna.mathews@wsj.com and David
Benoit at david.benoit@wsj.com
(END) Dow Jones Newswires
May 09, 2020 02:47 ET (06:47 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
JP Morgan Chase (NYSE:JPM)
Historical Stock Chart
From Mar 2024 to Apr 2024
JP Morgan Chase (NYSE:JPM)
Historical Stock Chart
From Apr 2023 to Apr 2024